Vicriviroc maleate
CAS: 599179-03-0
Ref. 3D-ZYA17903
| 1mg | Descatalogado | ||
| 5mg | Descatalogado | ||
| 10mg | Descatalogado | ||
| 25mg | Descatalogado | ||
| 50mg | Descatalogado |
Información del producto
- (4,6-Dimethylpyrimidin-5-yl){4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}methanone (2Z)-but-2-enedioate (1:1)
- methanone, (4,6-dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]-, (2Z)-2-butenedioate (1:1)
- 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methylpiperidine (2Z)-2-butenedioate
Vicriviroc maleate is an antiviral compound that exhibits potent activity against HIV-1. It acts by blocking the interaction between the viral envelope protein gp120 and the chemokine receptor CCR5, thereby inhibiting viral entry into target cells. Vicriviroc maleate has been shown to have high specificity for CCR5 and does not affect other chemokine receptors, such as CXCR4. This compound is available in the form of microcapsules, which provide sustained release of the active ingredient over time. The microcapsules are formulated with caffeine, phenol and/or tartaric acid, peptidoglycan, fatty acid, sevelamer, potassium borate, dopamine, and other excipients to enhance stability and bioavailability. Vicriviroc maleate is water-soluble and can be easily administered orally or intravenously. It has also been studied for its potential effects on potassium channels and chemokine-mediated signaling pathways
